Efforts for genotype-based risk stratification in CPVT have been made, but current evidence suggests similarity between CASQ2- and RYR2-related CPVT natural history; Priori et al. [95] and Lehnart et al. [99] have compared affected individuals with and without RYR2 pathogenic variants and demonstrated a similar age of onset and natural history. Here, CASQ2 is linked to catecholaminergic polymorphic ventricular tachycardia.